Tumor expression of Fas ligand (CD95L) and the consequences

Current Opinion in Immunology

Volumn 10, Issue 5, 1998, Pages 564-572

  Walker, Paul R ^a   Saas, Philippe ^b   Dietrich, Pierre Yves ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b ETS de Franche Comte   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

APOPTOSIS; REVIEW; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 0031756099     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80225-2     Document Type: Article

References (73)

1. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
2. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:1998;243-248.
3. Wong B, Choi Y. Pathways leading to cell death in T cells. Curr Opin Immunol. 9:1997;358-364.
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
5. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
6. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol. 158:1997;4122-4128.
7. Saas P, Walker PR, Hahne M, Quiquerez A-L, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY. Fas Ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? of special interest J Clin Invest. 99:1997;1173-1178 In this report human and rodent astrocytoma cell lines, as well as most astrocytoma biopsies, were shown to express CD95 ligand. Both cell lines and, importantly, human astrocytoma cells tested ex vivo both induced apoptosis in CD95-expressing targets.
8. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French L, Schneider P, Bornand T, Fontana A, Lienard D, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
9. - (CT26) tumors was achieved after direct intratumoral injection of ADV-FasL, suggesting to the authors a possible therapeutic application.
10. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 184:1996;1075-1082.
11. + hepatocytes.
12. + tumor-infiltrating lymphocytes to apoptosis induced by autologous astrocytoma cells that express CD95L.
13. Hartmann K, Wagelie-Steffen AL, von Stebut E, Metcalfe DD. Fas (CD95, Apo-1) antigen expression and function in murine mast cells. J Immunol. 159:1997;4006-4014.
14. Ehl S, Hoffman-Rohrer U, Nagata S, Hentgartner H, Zinkernagel R. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol. 156:1996;2357-2360.
15. + cells. Elegant experiments with chimeric mice demonstrated that neutrophil recruitment and tumor rejection required CD95 expression on hematopoietic cells but not on stromal cells. Overall, the results from this study provide strong evidence for a proinflammatory role of CD95L.
16. Seino K-I, Kayagaki N, Tsukada N, Fukao K, Yagita H, Okumura K. Transplantation of CD95 ligand-expressing grafts. Influence of transplantation site and difficulty in protecting allo- and xenografts. of special interest Transplantation. 64:1997;1050-1054 This is the sole paper to date documenting the importance of anatomical site for a tumor expressing CD95 ligand. An efficient immune response was obtained in syngeneic mice when L5178Y lymphoma cells were transfected with CD95 ligand and were injected subcutaneously, whereas there was tumor growth when the same tumor cells were implanted under the kidney capsule.
17. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. of outstanding interest Nat Med. 3:1997;843-848 This reports an in vivo study in which CD95 ligand (CD95L) expressed on an allogeneic tumor led to a dramatic reduction of the allospecific immune response, although the tumor was still rejected. The immune parameters affected by the tumor (that expressed CD95L) were particularly well-characterized in this paper: frequencies of specific cytotoxic T lymphocytes and helper T cells were reduced; alloantibodies of both IgM and IgG subclasses were abolished. These effects played a more important role in a secondary response, when challenge with parental tumor cells resulted in a slightly delayed rejection of the tumor. It was also noted that the effect of CD95L was localized to the site of injection of the transfectants.
18. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA, Matis LA. The role of Fas in autoimmune diabetes. of outstanding interest Cell. 89:1997;17-24 This is not a study of a tumor expressing CD95 ligand (CD95L), but nevertheless a report of particular importance for cancer and the methodologies used to investigate the role of CD95L (Fas ligand). These are the only experiments published, as far as we are aware, that address the question of whether there is an in vivo dose effect for CD95L. The other important concept highlighted in this study is the possibility of in vivo induction of CD95. Indeed, these two effects influenced the pathological outcome in transgenic mice expressing CD95L on pancreatic β cells. A low level of CD95L was suggested to be insufficient to eliminate infiltrating T cells, which in turn could secrete cytokines capable of inducing CD95 on the β cells. This complex cascade of events led to β-cell autodestruction by apoptosis and a more severe diabetes than with transgenic β cells expressing high levels of CD95L. These elegant experiments demonstrate how in vivo cellular interactions can influence the final outcome of CD95L over-expression. It is clear that these data may also have significant implications for the interpretation of studies using CD95L-transfected tumors.
19. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med. 187:1998;123-128.
20. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol. 155:1995;4147-4154.
21. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood. 90:1997;1952-1959.
22. Dao T, Huleatt JW, Hingorani R, Crispe IN. Specific resistance of T cells to CD95-induced apoptosis during S phase of the cell cycle. J Immunol. 159:1997;4261-4267.
23. Hornung F, Zheng L, Lenardo MJ. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol. 159:1997;3816-3822.
24. Wong B, Arron J, Choi Y. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J Exp Med. 186:1997;1939-1944.
25. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol. 159:1997;3808-3815.
26. Algeciras A, Dockrell DH, Lynch DH, Paya CV. CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis. J Exp Med. 187:1998;711-720.
27. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JC, Green D, Swain SL. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med. 185:1997;1837-1849.
28. Stokes TA, Rymaszewski M, Arscott PL, Wang SH, Bretz JD, Bartron J, Baker JRJ. Constitutive expression of FasL and thyrocytes (technical comment). Science. 279:1998;2015.
29. Fiedler P, Schaetzlein CE, Eibel H. Constitutive expression of FasL and thyrocytes (technical comment). Science. 279:1998;2015.
30. Papoff G, Stassi G, De Maria R, Giordano C, Galluzzo A, Bagnasco M, Ruberti G, Testi R. Constitutive expression of FasL and thyrocytes (technical comment). Science. 279:1998;2015.
31. Oyaizu N, Kayagaki N, Yagita H, Pahwa S, Ikawa Y. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem Biophys Res Commun. 238:1997;670-675.
32. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. of outstanding interest J Exp Med. 186:1997;2045-2050 In this report, soluble or membrane-bound human CD95 ligand (CD95L, Fas ligand) demonstrated cytotoxic function that differed according to the T-cell target tested. Both forms of CD95L could kill peripheral blood T cells activated by concanavalin A; however, only membrane-bound CD95L either killed fresh peripheral blood T cells or killed umbilical cord T cells activated by cytokine/anti-CD28; furthermore, soluble CD95L could inhibit the function of membrane-bound CD95L. These studies thus indicate that the most potent form of CD95L for apoptosis induction is membrane-bound (see also [33] and [34]) but that this function must also take into account the type of target cell.
33. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. of outstanding interest Nat Med. 4:1998;31-36 In this parallel study to [32], a preferential cytotoxic activity was found for membrane-bound Fas ligand (CD95 ligand or CD95L) compared with soluble CD95L. A cleavage site in the CD95L sequence was identified and subsequent transfections with CD95L-deletion mutants allowed the generation of cells expressing high levels of CD95L at the surface, without releasing CD95L into the supernatant. Cytotoxicity of cells expressing normal or noncleavable CD95 ligand was similar for W4 targets overexpressing CD95, but Jurkat cells and mouse hepatocytes were only killed efficiently by cells expressing noncleavable CD95L. The cytotoxicity of transfectants expressing normal CD95L could be enhanced by the addition of metalloproteinase inhibitors. As in [32], soluble CD95L could inhibit the cytotoxic function of membrane-bound CD95L; this is suggested to be a means of regulating cytoxicity in vivo.
34. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. of outstanding interest J Exp Med. 187:1998;1205-1213 In this independent study to [32] and [33], there is a further demonstration of higher cytotoxic activity of membrane-bound CD95 ligand (CD95L) compared to the soluble version. Cross-linking of soluble CD95L elicited a highly cytotoxic effect, probably not by increasing binding efficiency to CD95 but rather by creating large aggregates of CD95 - leading to efficient death-signal transduction. A cleavage site of CD95L was determined, which was not the same as that defined in [33] - perhaps reflecting different metalloproteinases present in the host cells used for transfection. Finally, another functionally active form of CD95L was defined that was unprocessed, membrane-bound and associated with vesicles or membrane fragments rather than whole cells. Such CD95L was released from transfected Neuro-2a cells, thought to have low protease-processing activity. The status of other tumor cell lines transfected with CD95L for in vivo studies clearly deserves investigation.
35. Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Okumura K, Yagita H. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA. 94:1997;3914-3919.
36. Suda T, Tanaka M, Miwa K, Nagata S. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol. 157:1996;3918-3924.
37. Faris M, Kokt N, Latinis K, Kasibhatla S, Green DR, Koretzky GA, Nel A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol. 160:1998;134-144.
38. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol. 6:1994;1567-1574.
39. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC. Human monocytic cells contain high levels of intracellular Fas ligand. Rapid release following cellular activation. of special interest J Immunol. 159:1997;1594-1598 This paper showed that the major pool of Fas ligand (CD95 ligand) expressed by monocytic cells (an acute monocytic leukemia cell line as well as normal peripheral monocytes) was intracellular rather than at the cell surface, but it could be rapidly mobilized after cell activation. In addition to conceptual implications, these findings evidently have practical significance for the detection of CD95 ligand protein.
40. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshimo K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 182:1995;1777-1783.
41. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface Apo-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol. 25:1995;2303-2307.
42. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, et al. Fas ligand in human serum. Nat Med. 2:1996;317-322.
43. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, Krammer PH, Galle PR. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 272:1997;28191-28193.
44. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today. 16:1995;569-574.
45. Freiberg RA, Spencer DM, Choate KA, Duh HJ, Schreiber SL, Crabtree GR, Khavari PA. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol. 108:1997;215-219.
46. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res. 17:1997;3253-3258.
47. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol. 28:1998;973-982.
48. An S, Yap D, Knox KA. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells. Cell Immunol. 181:1997;139-152.
49. Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R, Dorken B. Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/Apo-1) ligand expression and function. Eur J Immunol. 27:1997;1029-1034.
50. Xerri L, Devilard E, Hassoun J, Haddad P, Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia. 11:1997;1868-1877.
51. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, Geley S, Kofler R, Greil R. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood. 90:1997;12-20.
52. Ohshima K, Suzumiya J, Shimazaki K, Kato A, Tanaka T, Kanda M, Kikuchi M. Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage. Histopathology. 31:1997;444-450.
53. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 2:1996;574-577.
54. Perzova R, Loughran TP Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Brit J Haematol. 97:1997;123-126.
55. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7:1997;863-869.
56. of special interest Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T, Nickoloff BJ. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). of special interest J Clin Invest. 101:1998;33-39 This paper examined the possible role of CD95 ligand (CD95L) in the context of two different consequences of exposure of skin to UV light. In the case of sunlight-induced basal cell carcinoma there was CD95L expression (also see [57]), but no functional tests were performed. For UV-B irradiated nontumoral psoriatic skin there was an upregulation of CD95L expression by keratinocytes, correlated with elimination of intraepidermal T cells and disease remission. In vitro, UV-B-treated normal cultured keratinocytes acquired the ability to kill CD95-transfected lymphoma cells.
57. Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferon- alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest. 100:1997;2691-2696 As in [56], CD95 ligand expression was demonstrated on basal cell carcinoma cells but, here, functional activity is also shown. After intralesional IFN-α treatment, CD95 expression was induced on tumor cells; it was correlated with apoptosis and tumor regression. Autocrine or fratricidal interactions between CD95 and CD95L were proposed as the mechanism.
58. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC III, Birchenall-Roberts MC. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res. 57:1997;881-890.
59. Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Bamberger CM, Asa SL. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab. 82:1997;3173-3175.
60. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells- A mechanism of immune evasion? Nat Med. 2:1996;1361-1366.
61. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. of special interest Cancer Res. 57:1997;1007-1012 This demonstrated that the majority of human lung carcinoma biopsies and cell lines expressed Fas ligand (CD95 ligand) and that two non-small cell lung carcinoma cell lines killed Jurkat targets in a manner dependent on CD95 ligand.
62. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (Apo-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:1997;3823-3829.
63. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab. 83:1998;427-431.
64. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. of special interest Cancer Res. 58:1998;1741-1749 This represents a particularly thorough characterization of CD95 ligand expression in pancreatic adenocarcinoma, using a wide spectrum of antibodies and techniques (reverse-transcriptase polymerase chain reaction, immunohistochemistry, western blotting, flow cytometry and functional tests). Despite CD95 expression, pancreatic tumor cells were largely resistant to soluble CD95 ligand or anti-CD95 agonistic antibody; this was associated with high levels of a Fas-associated phosphatase 1 (FAP-1).
65. Sugihara A, Saiki S, Tsuji M, Tsujimura T, Nakata Y, Kubota A, Kotake T, Terada N. Expression of Fas and Fas ligand in the testes and testicular germ cell tumors: an immunohistochemical study. Anticancer Res. 17:1997;3861-3865.
66. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 99:1997;403-413.
67. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (Apo-1/Fas) system in drug- resistant cells. Leukemia. 11:1997;1833-1841.
68. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:1997;3331-3334.
69. Bauer MKA, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K. Role of reactive oxygen intermediates in activation-induced CD95 (apo-1/Fas) ligand expression. J Biol Chem. 273:1998;8048-8055.
70. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 375:1995;497-500.
71. Xu XN, Screaton GR, Gotch FM, Dong T, Tan R, Almond N, Walker B, Stebbings R, Kent K, Nagata S, et al. Evasion of cytotoxic T lymphocyte (CTL) responses by nef- dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med. 186:1997;7-16.
72. Chen X, Zachar V, Zdravkovic M, Guo M, Ebbesen P, Liu X. Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotropic virus type I Tax transactivator. J Gen Virol. 78:1997;3277-3285.
73. Chlichlia K, Busslinger M, Peter ME, Walczak H, Krammer PH, Schirrmacher V, Khazaie K. ICE-proteases mediate HTLV-I Tax-induced apoptotic T-cell death. Oncogene. 14:1997;2265-2272.